{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:27:32Z","timestamp":1793788052116,"version":"4.6.1"},"update-to":[{"DOI":"10.1002\/14651858.cd007654.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"reference-count":148,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007654.pub6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:33:08Z","timestamp":1781868788000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term effects of weight-reducing drugs in people with hypertension"],"prefix":"10.1002","volume":"2026","author":[{"given":"Ulrike","family":"Spary-Kainz","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-1435","authenticated-orcid":false,"given":"Nicole","family":"Posch","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Radl-Karimi","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Jeitler","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"},{"name":"Institute for Medical Informatics, Statistics and Documentation; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Krenn","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Siebenhofer","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"},{"name":"Institute for General Practice; Goethe University; Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Statistics and Documentation; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Horvath","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"},{"name":"Klinikum Bad Gleichenberg; Bad Gleichenberg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Winterholer","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Semlitsch","sequence":"additional","affiliation":[{"name":"Institute of General Practice and Evidence-Based Health Services Research; Medical University of Graz; Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"10.1002\/14651858.CD007654.pub6-BIB0001|cit1","unstructured":"World Health Organization Global report on hypertension. The race against a silent killer. 2023 Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240081062"},{"issue":"7653","key":"10.1002\/14651858.CD007654.pub6-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub6-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.amjhyper.2007.06.007","article-title":"Sedentary behaviors and the risk of incident hypertension: the SUN Cohort","volume":"20","author":"Beunza","year":"2007","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"107915","DOI":"10.1016\/j.ypmed.2024.107915","article-title":"Association between leisure sedentary behaviors and hypertension risk: z prospective cohort study and two-sample Mendelian randomization analysis in Europeans","volume":"181","author":"Li","year":"2024","journal-title":"Preventive Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","article-title":"Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children","volume":"36","author":"Rabi","year":"2020","journal-title":"Canadian Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub6-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0007|cit7","unstructured":"McEvoy J McCarthy C Bruno R Brouwers S Canavan M Ceconi C 2024 ESC Guidelines for the management of elevated blood pressure and hypertension European Heart Journal 2024 45 38 3912 4018 doi.org\/10.1093\/eurheartj\/ehae178"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0008|cit8","unstructured":"National Institute for Health and Care Excellence (NICE) Hypertension in adults: diagnosis and management Available from: https:\/\/www.nice.org.uk\/guidance\/ng136"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archinte.168.6.571","article-title":"Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis","volume":"168","author":"Horvath","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363(10)","author":"James","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0011|cit11","unstructured":"European Medicines Agency (EMA) Press release - European Medicines Agency recommends suspension of marketing authorisations for sibutramine Available from: https:\/\/www.ema.europa.eu\/system\/files\/documents\/press-release\/wc500069995_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0012|cit12","unstructured":"European Medicines Agency (EMA) Questions and answers on the suspension of medicines containing sibutramine Available from: https:\/\/www.ema.europa.eu\/system\/files\/documents\/referral\/wc500094238_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0013|cit13","unstructured":"Recommendation on a regulatory decision for Meridia (sibutramine) http:\/\/wayback.archive-it.org\/7993\/20170113112219\/http:\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM228795.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0014|cit14","unstructured":"Press release: [Abbott setzt Vertrieb seiner Medikamente mit dem Wirkstoff Sibutramin zur Behandlung von Adipositas in den L\u00e4ndern der Europ\u00e4ischen Union aus.] 2010 Available from: https:\/\/www.abbott.de\/press\/show\/e7340\/e19695\/e18095\/Sibutramin_210110_Theobald_de.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0015|cit15","unstructured":"FDA news release: Abbott Laboratories agrees to withdraw its obesity drug Meridia Available from: https:\/\/wayback.archive-it.org\/7993\/20170112215610\/http:\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2010\/ucm228812.htm"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0016|cit16","unstructured":"Colman EG FDA rimonabant briefing document. Endocrine and Metabolic Drugs Advisory Committee. 2007 Available from: https:\/\/wayback.archive-it.org\/7993\/20170405052424\/https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4306b1-fda-backgrounder.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0017|cit17","unstructured":"European Medicines Agency (EMA) Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) Available from: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-and-answers-recommendation-suspend-marketing-authorisation-acomplia-rimonabant_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0018|cit18","unstructured":"European Medicines Agency (EMA) Press release - the European Medicines Agency recommends suspension of the marketing authorisation of Acomplia Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/european-medicines-agency-recommends-suspension-marketing-authorisation-acomplia_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0019|cit19","unstructured":"European Medicines Agency (EMA) Public statement on Acomplia (rimonabant) - withdrawal of the marketing authorisation in the European Union Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-acomplia-withdrawal-marketing-authorisation-european-union_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0020|cit20","unstructured":"Qsymia (phentermine and topiramate extended-release) - approval letter Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/022580Orig1s000Approv.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0021|cit21","unstructured":"Belviq (lorcaserin hydrochloride) - approval letter https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/022529Orig1s000ltr.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0022|cit22","unstructured":"Contrave (naltrexone hydrochloride\/bupropion hydrochloride) - approval letter Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/200063Orig1s000Approv.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0023|cit23","unstructured":"Saxenda (liraglutide) - approval letter Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/206321Orig1s000ltr.pdf"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0025|cit25","unstructured":"European Medicines Agency (EMA) Mysimba (naltrexone\/bupropion) - EPAR summary for the public Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mysimba-epar-summary-public_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0026|cit26","unstructured":"European Medicines Agency (EMA) Saxenda (liraglutide) - EPAR summary for the public Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/saxenda-epar-summary-public_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0027|cit27","unstructured":"Health Canada. Drug Product Database \u2013 Contrave (DIN 02472945) https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=96230"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0028|cit28","unstructured":"Approval of saxenda (liraglutide) for chronic weight management in adults with overweight or obesity https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=92226"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0029|cit29","unstructured":"Department of Health Approval of Liraglutide Available from: https:\/\/www.tga.gov.au\/resources\/artg\/225804"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0030|cit30","unstructured":"Department of Health Approval naltrexone\/bupropion ARTG https:\/\/www.tga.gov.au\/resources\/prescription-medicines-registrations\/contrave-inova-pharmaceuticals-australia-pty-ltd"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0031|cit31","unstructured":"Korean Ministry of Food and Drug Safety Approval liraglutide https:\/\/nedrug.mfds.go.kr\/CEAAA21?sort=&sortOrder=&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemEngName=&entpEngName=&ingrEngName=liraglutide&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&cancelCode=&etcOtcCode=&makeMaterialGb=&startPermitDate=&endPermitDate="},{"key":"10.1002\/14651858.CD007654.pub6-BIB0032|cit32","unstructured":"Korean Ministry of Food and Drug Safety Naltrexone\/bupropion - approval information https:\/\/nedrug.mfds.go.kr\/CEAAA21?sort=&sortOrder=&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemEngName=&entpEngName=&ingrEngName=naltrexone%2Fbupropion&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&cancelCode=&etcOtcCode=&makeMaterialGb=&startPermitDate=&endPermitDate="},{"key":"10.1002\/14651858.CD007654.pub6-BIB0033|cit33","unstructured":"European Medicines Agency (EMA) Questions and answers on the withdrawal of the marketing authorisation application for Belviq (lorcaserin) Available from: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-and-answers-withdrawal-marketing-authorisation-application-belviq_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0034|cit34","unstructured":"Eisai to Voluntarily Withdraw BELVIQ\u00ae\/BELVIQ XR\u00ae in the U.S. Available from: https:\/\/eisai.mediaroom.com\/2020-02-13-Eisai-to-Voluntarily-Withdraw-BELVIQ-R-BELVIQ-XR-R-in-the-U-S"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0035|cit35","unstructured":"Drug safety communication - FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market Available from: https:\/\/www.fda.gov\/media\/135189\/download"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0036|cit36","unstructured":"European Medicines Agency (EMA) Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine\/topiramate) Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0037|cit37","unstructured":"European Medicines Agency (EMA) Scientific conclusions and grounds for refusal of the marketing authorisation for Qsiva (13 June 2013) Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0038|cit38","unstructured":"Wegovy (semaglutide) - approval letter Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/215256Orig1s000ltr.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0039|cit39","unstructured":"Zepbound (tirzepatide) - approval letter Available from: Approval Letter_217806Orig1s000ltr.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0040|cit40","unstructured":"European Medicines Agency (EMA) Wegovy (semaglutide) - an overview of Wegovy and why it is authorised in the EU Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/wegovy-epar-medicine-overview_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0041|cit41","unstructured":"European Medicines Agency (EMA) Mounjaro (tirzepatide): EPAR - medicine overview Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mounjaro-epar-medicine-overview_en.pdf"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0042|cit42","unstructured":"Approval of semaglutide https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=101774"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0043|cit43","unstructured":"Approval of tirzepatide https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=104066"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0044|cit44","unstructured":"Department of Health WEGOVY 1.7 mg semaglutide 2.27 mg\/mL solution for injection pre-filled pen with pre-assembled needle (356287) - approval information https:\/\/www.tga.gov.au\/resources\/artg\/356287"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0045|cit45","unstructured":"Department of Health Approval of tirzepatide https:\/\/www.tga.gov.au\/resources\/artg\/379331"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0046|cit46","unstructured":"Korean Ministry of Food and Drug Safety Approval semaglutide https:\/\/nedrug.mfds.go.kr\/CEAAA21?sort=&sortOrder=&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemEngName=&entpEngName=&ingrEngName=semaglutide&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&cancelCode=&etcOtcCode=&makeMaterialGb=&startPermitDate=&endPermitDate="},{"key":"10.1002\/14651858.CD007654.pub6-BIB0047|cit47","unstructured":"Korean Ministry of Food and Drug Safety Approval tirzepatide https:\/\/nedrug.mfds.go.kr\/CEAAA21?sort=&sortOrder=&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemEngName=&entpEngName=&ingrEngName=tirzepatide&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&cancelCode=&etcOtcCode=&makeMaterialGb=&startPermitDate=&endPermitDate="},{"issue":"9555","key":"10.1002\/14651858.CD007654.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","article-title":"Drug treatments for obesity: orlistat, sibutramine, and rimonabant","volume":"369","author":"Padwal","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub6-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring, Md.)"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2147\/DDDT.S55587","article-title":"Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: review of the data to date","volume":"8","author":"Caixas","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"issue":"1-2","key":"10.1002\/14651858.CD007654.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"23","key":"10.1002\/14651858.CD007654.pub6-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: a systematic update","volume":"23","author":"Forzano","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.17925\/EE.2022.18.1.10","article-title":"Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"18","author":"Kaneko","year":"2022","journal-title":"TouchREVIEWS in Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/obr.12015","article-title":"Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs","volume":"14","author":"Chan","year":"2013","journal-title":"Obesity Reviews: an Official Journal of the International Association for the Study of Obesity"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","article-title":"Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis","volume":"154","author":"Khera","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"LeBlanc EL Patnode CD Webber EM Redmond N Rushkin M O'Connor EA Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: an updated systematic review for the U.S. Preventive Services Task Force Agency for Healthcare Research and Quality (US). U.S. Preventive Services Task Force evidence syntheses, formerly systematic evidence reviews, report no.: 18-05239-EF-1 2018","DOI":"10.1001\/jama.2018.7777"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0058|cit58","doi-asserted-by":"crossref","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/1753-0407.12198","article-title":"Weight loss effect of glucagon-like peptide-1 mimetics on obese\/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2015","journal-title":"Journal of Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"9932","key":"10.1002\/14651858.CD007654.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s11606-021-06655-2","article-title":"Dissociation between long-term weight loss intervention and blood pressure: an 18-month randomized controlled trial","volume":"36","author":"Gepner","year":"2021","journal-title":"Journal of General Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654.pub5","article-title":"Long-term effects of weight-reducing drugs in people with hypertension","author":"Siebenhofer","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654","article-title":"Long-term effects of weight-reducing drugs in hypertensive patients","author":"Matyas","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0065|cit65","unstructured":"Higgins JPT Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews Cochrane: London"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub6-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"371","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654.pub4","article-title":"Long-term effects of weight-reducing drugs in people with hypertension","author":"Siebenhofer","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"27","key":"10.1002\/14651858.CD007654.pub6-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"E797","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0069|cit69","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 The Cochrane Collaboration, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0070|cit70","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Canadian Medical Association Journal"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e5673","DOI":"10.1371\/journal.pone.0005673","article-title":"Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials","volume":"4","author":"Musini","year":"2009","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0073|cit73","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). The Cochrane Collaboration, 2023 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0074|cit74","unstructured":"Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension Available from: iqwig.de\/download\/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf 2006 19 119"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0076|cit76","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub6-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub6-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub6-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"39","key":"10.1002\/14651858.CD007654.pub6-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart (British Cardiac Society)"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654.pub2","article-title":"Long-term effects of weight-reducing drugs in hypertensive patients","author":"Siebenhofer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0197-2456(01)00165-9","article-title":"Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience","volume":"22","author":"Torgerson","year":"2001","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub6-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000083662","article-title":"Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: a randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise)","volume":"5","author":"Cocco","year":"2005","journal-title":"Heart Drug"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub6-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0087|cit87","unstructured":"Buse JB Smith SR Gilder K Shan K Halseth A Effect of naltrexone\/bupropion on cardiovascular events in overweight and obese participants with type 2 diabetes and cardiovascular risk factors in a large randomized, double-blind study Diabetes 2017 A557"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0088|cit88","unstructured":"Wolski K Light study - data on hypertensive subgroup [personal communication] Email to: T Semlitsch"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0089|cit89","unstructured":"Halseth A Gilder K Shan K Acevedo L Buse J Effect on body weight of naltrexone\/bupropion in overweight and obese participants with cardiovascular risk factors in a large randomized double-blind study Obesity Facts 2017 46"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0090|cit90","unstructured":"Halseth A Gilder K Shan K Acevedo L Smith S Naltrexone\/bupropion is well tolerated and had no effect on serious adverse events in participants receiving antidepressant medication, including SSRIs, in a large randomized double-blind study Obesity Facts 2017 46"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0091|cit91","unstructured":"Smith SR Buse JB Gilder K Shan K Halseth A Effect on body weight of naltrexone\/bupropion in overweight and obese participants with type 2 diabetes and cardiovascular risk factors in a large, randomized, double-blind study Diabetes 2017 A556"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub6-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-8902.2004.00359.x","article-title":"Effects of orlistat on obesity-related diseases - a six-month randomized trial","volume":"6","author":"Guy-Grand","year":"2004","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub6-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.amjcard.2012.12.038","article-title":"Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index >27 kg\/m(2)","volume":"111","author":"Davidson","year":"2013","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0095|cit95","unstructured":"Ryan DH Garvey WT Day WW Achievement of composite of recommended goals in obese subjects with type 2 diabetes mellitus using extended-release phentermine\/topiramate in a 56-week weight loss intervention Endocrine Reviews 2012 (3 Meeting Abstracts)"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0096|cit96","unstructured":"Astrup AV Oppert JM Peterson CA Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine\/topiramate treatment in overweight\/obese subjects with type 2 diabetes Diabetologia 2012 S284 S285"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0097|cit97","unstructured":"Cheskin LJ Bowden CH Reduction of cardiovascular risk factors by magnitude of weight loss in obese and overweight subjects with >2 comorbidities Journal of General Internal Medicine 2013 S168"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0098|cit98","unstructured":"Garvey WT Henry RR Peterson CA Bowden CH Weight loss with controlled-release phentermine\/topiramate (PHEN\/TPM CR) reverses metabolic syndrome (MetS) and improves associated traits Diabetes 2011 A506"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Kahan S Karnawat S Effect of weight loss (Wl) on concomitant medication costs in obese\/overweight individuals with metabolic syndrome (METS) receiving phentermine\/topiramate extended-release (PHEN\/TPM ER) Value in Health 2015 A297","DOI":"10.1016\/j.jval.2015.03.1730"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0100|cit100","unstructured":"Cheskin LJ Peterson CA Improved cardiometabolic risk factors in overweight\/obese subjects receiving controlled-release phentermine\/topiramate (PHEN\/TPM CR) Diabetes 2012 A710"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Davidson M Bowden CH Day WW Weight loss and cardiovascular risk reduction over 2 years with controlled-release phentermine-topiramate Journal of the American College of Cardiology 2011 E545","DOI":"10.1016\/S0735-1097(11)60545-7"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0102|cit102","unstructured":"Finer N Jordan J Dvorak R Weight loss and improvements in blood pressure (BP) status associated with phentermine and topiramate extended-release (PHEN\/TPM ER) treatment in obese and overweight adults Obesity Facts 2013 45"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0103|cit103","unstructured":"Gadde K Najarian T Day WW Magnitude of weight loss experienced with a low-dose, controlled-release formulation of phentermine\/topiramate (PHEN\/TPM) may drive degree of cardiometabolic benefit Diabetes 2010"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0104|cit104","unstructured":"Gadde K Peterson C Troupin B Day WW 12-month weight loss and antihypertensive benefits with PHEN\/TPM in overweight and obese subjects with hypertension European Journal of Cardiovascular Prevention and Rehabilitation 2010 S2"},{"issue":"9774","key":"10.1002\/14651858.CD007654.pub6-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.[Erratum appears in Lancet. 2011 Apr 30;377(9776):1494]","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0106|cit106","unstructured":"Gadde KM Day WW Low-dose, controlled-release phentermine\/topiramate for reduction of weight, related risks in overweight\/obese adults with >2 comorbidities Obesity Reviews 2010 42 3"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0107|cit107","unstructured":"Garvey WT Gadde K Tam P Peterson C Changes in insulin sensitivity in overweight\/obese patients treated with low-dose, controlled-release phentermine\/topiramate (PHEN\/TPM) Diabetes 2010"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0108|cit108","unstructured":"Garvey WT Gadde K Wilson LF Peterson C Improvements in dyslipidemia and other cardiometabolic disease risk factors with low-dose, controlled-release phentermine\/topiramate (PHEN\/TPM) Diabetes 2010"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Gupta AK Church T Day WW Obesity treatment-induced weight loss improves resting blood pressure and reduces progression from prehypertension to hypertension in overweight\/obese adults Circulation 2013 (12 Meeting Abstracts)","DOI":"10.1161\/circ.127.suppl_12.AP027"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0110|cit110","unstructured":"Kushner RF Varghese ST Weight loss with phentermine and topiramate extended-release in obese and overweight subjects over 56 weeks Journal of General Internal Medicine 2013 S241"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0111|cit111","unstructured":"Rossner SK Sharma AM Troupin B Padwal RS Effects of extended-release phentermine\/topiramate on weight loss and blood pressure in obese subjects with type 2 diabetes mellitus Diabetologia 2012 S285"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub6-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40273-014-0182-6","article-title":"Cost-effectiveness analysis of Qsymia for weight loss","volume":"33","author":"Finkelstein","year":"2015","journal-title":"PharmacoEconomics"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0113|cit113","unstructured":"Garvey WT Troupin B Day WW Once-daily, low-dose, controlled-release phentermine\/topiramate results in significant clinical improvements in overweight\/obese patients with type 2 diabetes Diabetologia 2010 S308"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0114|cit114","unstructured":"Troupin B Hankin CS Low-dose controlled-release phentermine\/topiramate (PHEN\/TPM CR) results in significant weight loss and improves atherosclerotic biomarkers in overweight\/obese patients with obesity-related comorbidities Clinical Pharmacology and Therapeutics 2011 S39"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0115|cit115","unstructured":"Troupin B Hankin CS Magnitude of weight loss conferred by controlled-release low-dose phentermine\/topiramate (PHEN\/TPM CR) determines extent of cardiometabolic benefit Clinical Pharmacology and Therapeutics 2011 S38 S39"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0116|cit116","unstructured":"A clinical study to study the effect of lorcaserin tablets in the treatment of obesity https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2017\/05\/008655"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub6-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolicbenefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"issue":"9741","key":"10.1002\/14651858.CD007654.pub6-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropionon weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropionSR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Eff ects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub6-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006423.pub2","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0124|cit124","unstructured":"FDA reminds clinicians of liraglutide\u2019s risks for pancreatitis and cancer Available from: https:\/\/clinician.nejm.org\/fda-reminds-clinicians-liraglutides-risks-pancreatitis-cancer-FW201106140000002"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide eff ect and action indiabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub6-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub6-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"International Journal of Obesity (London)"},{"issue":"10077","key":"10.1002\/14651858.CD007654.pub6-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub6-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub6-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs pacebo one weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10278","key":"10.1002\/14651858.CD007654.pub6-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub6-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub6-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub6-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub6-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub6-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes & Metabolism"},{"issue":"19","key":"10.1002\/14651858.CD007654.pub6-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD007654.pub6-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"38","key":"10.1002\/14651858.CD007654.pub6-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD007654.pub6-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/oby.24202","article-title":"Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials","volume":"33","author":"Tchang","year":"2024","journal-title":"Obesity"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"10402","key":"10.1002\/14651858.CD007654.pub6-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub6-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub6-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/cd22-0029","article-title":"Efficacy and safety of tirzepatide in adults with type 2 diabetes: a perspective for primary care providers","volume":"41","author":"Kushner","year":"2023","journal-title":"Clinical Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD007654.pub6-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub6-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/01.HYP.0000165680.59733.d4","article-title":"Effects of weight loss in overweight\/obese individuals and long-term hypertension outcomes: a systematic review","volume":"45","author":"Aucott","year":"2005","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub6-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15344\/2456-8007\/2019\/131","article-title":"Cardiovascular risk reduction associated with pharmacological weight loss: a meta-analysis","volume":"4","author":"Kane","year":"2019","journal-title":"International Journal of Clinical Research Trials"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:48:15Z","timestamp":1793785695000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007654.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":148,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007654.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}